- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Rationale for Initiating Therapy with an Immuno-Oncology Drug
When deciding whether to recommend an immunotherapy agent, it is important to ensure that the drug is approved for the specific indication. In addition, because an immunotherapy agent can take several weeks to have an effect, it is important to consider the pace of the patient’s disease progression, says Andrew L. Pecora, MD.
Biomarkers are an essential part of decision making, although some biomarkers have not been found to be absolutely predictive. The greater number of mutations a cancer has, however, the greater the likelihood that an immuno-oncology drug will work, states Pecora.
About half of patients respond to immuno-oncology drugs when they are given in combination or sequentially, notes Pecora, and fewer when the drugs are given alone. There is some variability among the diagnostic tests, states Pecora, and there are many potential explanations. At times, the tissue sample is not representative of the tumor. Also, the microenvironment of the tumor is not static. The tumor could be leaving an inflammatory state where there would be a lot of PD-1 expression, for example, and going to a noninflammatory state. There are still many unanswered questions in terms of which biomarkers are the most important in which instances, adds Pecora.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Patient-Reported Outcomes Help to Uncover Frailty Patterns in Those With Acute COPD Exacerbations
April 22nd 2024Study findings demonstrate the pivotal role of patient-reported outcomes in identifying frailty among individuals experiencing acute exacerbations of chronic obstructive pulmonary disease (COPD).
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
